03.02.23 -- Scaling Cell Therapies For The Healthcare Industry

To provide a smooth transition from the lab to a CDMO, there are important factors you must first understand and steps to take prior to searching for and engaging with an external partner. 

Find out what steps you can take to reduce the risk of component shortages in medical devices and for the manufacture of drugs and biologics, and their consequences.

This streamlined process delivers complete custom cleanrooms from scratch in as little as four months from concept initiation.

To prepare allogeneic, or "donor-derived," CAR T cells for commercial scale, you must consider scale-up, aseptic processing, single-use systems, facility design, starting material, supply chain, and logistics.

Learn about the key stages of drug discovery and screening along with how to overcome key bottlenecks in screening mRNA-LNPs to rapidly develop genomic medicines.

We demonstrate a workflow that can be used to access broad plasma cell diversity and rapidly down-select lead candidates with functional profiling.

Learn how to navigate the complex challenges of accelerating therapies through clinical development to regulatory approval and commercialization.

With each batch of cell and gene therapy product representing a wealth of lifesaving potential, this biopharma company needed the right packaging solution for its relatively new therapy applications.

This presentation discusses an innovative manufacturing methodology and fill/finish approaches to accelerate T cell therapies to the commercial readiness phase.